Bionomics LtdNASDAQ:BNOX
- LAST PRICE0.9503
- TODAY'S CHANGE (%)-0.0096 (-1.0001%)
- Bid / Lots0.9503/ 3
- Ask / Lots0.9703/ 4
- Open / Previous Close0.9500 / 0.9599
- Day Range
- 52 Week Range
- Volume7,528
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BNOX |
|---|---|---|
| 09:32 ET | 1037 | 0.95 |
| 09:39 ET | 500 | 0.9501 |
| 09:45 ET | 831 | 0.9501 |
| 09:56 ET | 175 | 0.969501 |
| 10:03 ET | 2692 | 0.95 |
| 10:37 ET | 1133 | 0.96515 |
| 11:09 ET | 1000 | 0.9503 |
Industry Peers
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bionomics Ltd | --- | 0.0x | --- |
Company Information
Bionomics Ltd is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on development of novel drug candidates focused on the treatment of serious central nervous system disorders. It is developing novel allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. It is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Its α7 Receptor Positive Allosteric Modulators (PAMs) pipeline is targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. The Company’s CNS pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels.
Contact Information
- Headquarters
- 200 Greenhill RoadTHEBARTON, SA, Australia 5063
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Alan Fisher
- President, Chief Executive Officer
- Spyridon Papapetropoulos
- Chief Financial Officer
- Timothy Cunningham
- Vice President - Clinical Development
- Liz Doolin
- Non-Executive Chairman of the Board
- Errol De Souza
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | --- |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | --- |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | --- |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
